Sustained-Release Corticosteroid Options

• Type of Material: Article
• Authors: Mariana Cabrera, University of Miami Miller School of Medicine; Steven Yeh, Emory University; Thomas A Albini, University of Miami Miller School of Medicine
• Language: English
• Date: 2014-07-23
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2014 Mariana Cabrera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1155/2014/164692
• Title of Journal or Parent Work: Journal of Ophthalmology
• Volume: 2014
• Start Page: 164692
• End Page: 164692
• Keywords: Ophthalmology; MULTICENTER; MEDICINE, RESEARCH & EXPERIMENTAL; OPHTHALMOLOGY; DEXAMETHASONE INTRAVITREAL IMPLANT; Research & Experimental Medicine; CLINICAL-TRIAL; VITREOUS INSERTS; DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; EYES; Science & Technology; Medicine, Research & Experimental; Life Sciences & Biomedicine; FLUOCINOLONE ACETONIDE IMPLANT; POSTERIOR UVEITIS; PHARMACOKINETICS
• Research Categories: Health Sciences, Opthamology

Abstract

Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis. Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA). Each has different physical characteristics and duration effect and has been approved for different indications. Herein we provide a summary of the current clinical knowledge regarding these implants.